A Miss for FMT in Ulcerative Colitis, Additional Upadacitinib Benefits in Crohn’s

Miguel Regueiro, MD

Professor of Medicine
Chief of the Digestive
Disease Institute
Cleveland Clinic, Cleveland

By Miguel Regueiro, MD, with Marcus A. Banks

This month’s The Regueiro Report looks at two distinct issues: the viability of using fecal microbiota transplantation to treat active ulcerative colitis and evidence of additional benefits of upadacitinib (Rinvoq, AbbVie) for people with Crohn’s disease beyond the traditional outcomes of clinical response, remission and endoscopic